Cargando…

587. HIV Care Outcomes Among PWID in San Francisco, 2009–2015

BACKGROUND: Around 16% of HIV infections in the United States are among persons who inject drugs (PWID). PWID have a higher mortality than other persons living with HIV due to delayed diagnosis, lower use of antiretroviral therapy (ART), and other factors. Understanding the specific barriers to viro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Nathan, Welty, Susie, Reza, Tania, Sears, David, McFarland, Willi, Raymond, H Fisher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253420/
http://dx.doi.org/10.1093/ofid/ofy210.594
_version_ 1783373490147033088
author Kim, Nathan
Welty, Susie
Reza, Tania
Sears, David
McFarland, Willi
Raymond, H Fisher
author_facet Kim, Nathan
Welty, Susie
Reza, Tania
Sears, David
McFarland, Willi
Raymond, H Fisher
author_sort Kim, Nathan
collection PubMed
description BACKGROUND: Around 16% of HIV infections in the United States are among persons who inject drugs (PWID). PWID have a higher mortality than other persons living with HIV due to delayed diagnosis, lower use of antiretroviral therapy (ART), and other factors. Understanding the specific barriers to virologic suppression, however, is challenging as PWID are less likely to engage in care. Here we present trends in HIV care indicators for PWID in San Francisco from 2009 to 2015, using a novel system of behavioral health surveys. These data will inform international and local initiatives for population-level HIV control, such as San Francisco’s “Getting to Zero” initiative and UNAIDS’s “90-90-90” targets. METHODS: We used data from serial cross-sectional surveys of PWID conducted in 2009, 2012, and 2015 as part of the CDC-led National HIV Behavioral Surveillance system. PWID were recruited using respondent-driven sampling, in which PWID refer their peers to the surveys. We tracked the number of PWID who were: (i) living with HIV, (ii) knew their HIV status, (iii) were on ART, and (iv) for 2015 only, were virally suppressed (self-reported). RESULTS: HIV prevalence among PWID was 11.4% in 2009, 12.0% in 2012, and 16.8% in 2015. The percentage of PWID living with HIV who knew their HIV+ diagnosis remained stable (57.8% in 2009; 57.3% in 2012) before increasing to 83.3% in 2015. Among PWID who knew their HIV status, the proportion reporting they were currently taking ART declined from 73.8% in 2009 to 66.3% in 2012 to 64.1% in 2015. In 2015, the only year the question was asked, 87.2% of HIV+ PWID reported that their most recent viral load was suppressed. CONCLUSION: We successfully tracked trends in engagement in HIV care among PWID from 2009 to 2015. Our data are notable for an apparent improvement in HIV diagnosis over time, a persistent gap in treatment with ART, and—in 2015—a relatively high rate of self-reported viral suppression when on ART. All three measures fall short of the UNAIDS 90-90-90 goals. The decline in getting PWID on ART from 2009 to 2015 is particularly concerning and warrants additional linkage to care and retention efforts. This is especially important given the high rates of viral suppression PWID can achieve once on ART, as seen in our study and other reports from published literature. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253420
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62534202018-11-28 587. HIV Care Outcomes Among PWID in San Francisco, 2009–2015 Kim, Nathan Welty, Susie Reza, Tania Sears, David McFarland, Willi Raymond, H Fisher Open Forum Infect Dis Abstracts BACKGROUND: Around 16% of HIV infections in the United States are among persons who inject drugs (PWID). PWID have a higher mortality than other persons living with HIV due to delayed diagnosis, lower use of antiretroviral therapy (ART), and other factors. Understanding the specific barriers to virologic suppression, however, is challenging as PWID are less likely to engage in care. Here we present trends in HIV care indicators for PWID in San Francisco from 2009 to 2015, using a novel system of behavioral health surveys. These data will inform international and local initiatives for population-level HIV control, such as San Francisco’s “Getting to Zero” initiative and UNAIDS’s “90-90-90” targets. METHODS: We used data from serial cross-sectional surveys of PWID conducted in 2009, 2012, and 2015 as part of the CDC-led National HIV Behavioral Surveillance system. PWID were recruited using respondent-driven sampling, in which PWID refer their peers to the surveys. We tracked the number of PWID who were: (i) living with HIV, (ii) knew their HIV status, (iii) were on ART, and (iv) for 2015 only, were virally suppressed (self-reported). RESULTS: HIV prevalence among PWID was 11.4% in 2009, 12.0% in 2012, and 16.8% in 2015. The percentage of PWID living with HIV who knew their HIV+ diagnosis remained stable (57.8% in 2009; 57.3% in 2012) before increasing to 83.3% in 2015. Among PWID who knew their HIV status, the proportion reporting they were currently taking ART declined from 73.8% in 2009 to 66.3% in 2012 to 64.1% in 2015. In 2015, the only year the question was asked, 87.2% of HIV+ PWID reported that their most recent viral load was suppressed. CONCLUSION: We successfully tracked trends in engagement in HIV care among PWID from 2009 to 2015. Our data are notable for an apparent improvement in HIV diagnosis over time, a persistent gap in treatment with ART, and—in 2015—a relatively high rate of self-reported viral suppression when on ART. All three measures fall short of the UNAIDS 90-90-90 goals. The decline in getting PWID on ART from 2009 to 2015 is particularly concerning and warrants additional linkage to care and retention efforts. This is especially important given the high rates of viral suppression PWID can achieve once on ART, as seen in our study and other reports from published literature. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253420/ http://dx.doi.org/10.1093/ofid/ofy210.594 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Kim, Nathan
Welty, Susie
Reza, Tania
Sears, David
McFarland, Willi
Raymond, H Fisher
587. HIV Care Outcomes Among PWID in San Francisco, 2009–2015
title 587. HIV Care Outcomes Among PWID in San Francisco, 2009–2015
title_full 587. HIV Care Outcomes Among PWID in San Francisco, 2009–2015
title_fullStr 587. HIV Care Outcomes Among PWID in San Francisco, 2009–2015
title_full_unstemmed 587. HIV Care Outcomes Among PWID in San Francisco, 2009–2015
title_short 587. HIV Care Outcomes Among PWID in San Francisco, 2009–2015
title_sort 587. hiv care outcomes among pwid in san francisco, 2009–2015
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253420/
http://dx.doi.org/10.1093/ofid/ofy210.594
work_keys_str_mv AT kimnathan 587hivcareoutcomesamongpwidinsanfrancisco20092015
AT weltysusie 587hivcareoutcomesamongpwidinsanfrancisco20092015
AT rezatania 587hivcareoutcomesamongpwidinsanfrancisco20092015
AT searsdavid 587hivcareoutcomesamongpwidinsanfrancisco20092015
AT mcfarlandwilli 587hivcareoutcomesamongpwidinsanfrancisco20092015
AT raymondhfisher 587hivcareoutcomesamongpwidinsanfrancisco20092015